GleamWall
中文EN

ABUS Arbutus Biopharma Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 1447028 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,142.6%
TTM net income YoY620.2%
TTM EPS YoY587.0%
Revenue 3-yr CAGR101.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin81.1%
Net margin121.2%
FCF margin—
EBITDA margin81.1%

Returns

ROE269.6%
ROA100.6%
ROIC (approx.)—
Asset turnover0.83x

Leverage & solvency

Liabilities / assets74.8%
Debt / equity0.00x
Current ratio1.40x
Interest coverage2,299.38x

Cash quality & payout

Operating cash flow / net income1.00x
Accruals ratio-0.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$14.08M$6.17M
R&D expense$25.24M$54.04M
SG&A expense$15.89M$22.11M
Operating income-$38.16M-$76.32M
Interest expense$97,000$137,000
Pretax income$11.95M-$1.67M
Income tax$0$0
Net income-$33.50M-$69.92M
EBITDA-$37.80M-$74.94M
EPS (basic)-0.17-0.38
EPS (diluted)-0.17-0.38
Weighted avg. shares (diluted)191.60M185.61M
Balance sheet
Cash & equivalents$18.01M$36.33M
Short-term investments$73.46M$86.29M
Receivables$1.45M$2.41M
Current assets$94.46M$127.32M
PP&E, net$32,000$3.31M
Total assets$94.62M$131.71M
Current liabilities$6.01M$15.62M
Long-term debt$0$0
Total debt$0$0
Total liabilities$18.04M$34.34M
Shareholders' equity$76.58M$97.37M
Net debt-$18.01M-$36.33M
Shares outstanding192.53M189.96M
Cash flow statement
Operating cash flow-$39.64M-$64.85M
Capital expenditure$0$182,000
Free cash flow-$39.64M-$65.03M
Investing cash flow$15.58M$22.95M
Financing cash flow$5.72M$52.00M
Depreciation & amortization$363,000$1.38M
Stock-based compensation$6.95M$8.99M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.